Retrospective economic and outcomes analyses using non-US databases: A review

PharmacoEconomics

Volumn 25, Issue 7, 2007, Pages 563-576

  Shi, Lizheng ^a   Wu, Eric Q ^b   Hodges, Meredith ^a   Yu, Andrew ^b   Birnbaum, Howard ^b  

^a TULANE UNIVERSITY   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CELECOXIB; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

CHECKLIST; DATA ANALYSIS; DATA BASE; DRUG COST; ECONOMIC ASPECT; EXTERNAL VALIDITY; HEALTH CARE COST; HEALTH ECONOMICS; INTERNAL VALIDITY; MEDICAL SOCIETY; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS;

DATABASES, FACTUAL; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; EUROPE; FEMALE; HUMANS; MALE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES;

EID: 34447254244     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725070-00003     Document Type: Review

References (47)

1. Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999; 16 (1): 1-8
2. Ward RA, Brier ME. Retrospective analyses of large medical databases: what do they tell us? J Am Soc Nephrol 1999; 10: 429-32
3. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observation studies, and the hierarchy of research designs. N Engl J Med 2000 Jun 22; 342: 1887-92
4. Benson K, Hartz AJ. A comparison of observation studies and randomized, controlled trials. N Engl J Med 2000 Jun 22; 342: 1878-86
5. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies: report of the ISPOR Task Force on Retrospective Databases. Value Health 2003 Mar- Apr; 6: 90-7
6. Jick S, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136 (10): 1231-6
7. Moride Y, Ducruet T, Boivin JF, et al. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. Can J Clin Pharmacol 2005 Jun 17; 12 (2): 201-11
8. Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005 Jan 19; 330: 230-3
9. Quach C, Collet JP, LeLorier J. Acute otitis media in children: a retrospective analysis of physician prescribing patterns. Br J Clin Pharmacol 2004; 57 (4): 500-5
10. Mahmud SM, Fong B, Fahmy N, et al. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol 2006 Jan; 175: 78-83
11. Vanasse A, Dagenais P, Niyonsenga T, et al. Bone mineral density measurement and osteoporosis treatment after fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord 2005 Jun 21; 6: 33
12. Nelson CH, Park J. The nature and correlates of unmet health care needs in Ontario, Canada. Soc Sci Med 2006 May; 62 (9): 2291-300
13. Wang JL, Patten SB, Williams JV, et al. Help-seeking behaviors of individuals with mood disorders. Can J Psychiatry 2005 Sep; 50 (10): 652-9
14. Nguyen CT, Fournier L, Bergeron L, et al. Correlates of depressive and anxiety disorders among young Canadians. Can J Psychiatry 2005 Sep; 50 (10): 620-8
15. Vasiliadis HM, Lesage A, Adair C, et al. Service use for mental health reasons: cross-provincial differences in rates, determinants, and equity of access. Can J Psychiatry 2005 Sep; 50 (10): 614-9
16. Beck CA, Williams JV, Wang JL, et al. Psychotropic medication use in Canada. Can J Psychiatry 2005 Sep; 50 (10): 605-13
17. Kairouz S, Nadeau L, Siou GL. Area variations in the prevalence of substance abuse and gambling behaviors and problems in Quebec: a multilevel analysis. Can J Psychiatry 2005 Sep; 50 (10): 591-8
18. Patten SB. The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Popul Health Metr 2004 Nov 1; 2 (1): 9
19. Vissandjee B, Desmeules M, Zheynuan C, et al. Integrating socio-economic determinants of Canadian women's health. BMC Women's Health 2004 Aug 25; 4 Suppl. 1: S34
20. Ross N. Community belonging and health. Health Rep 2002 Mar; 13 (3): 33-9
21. Currie SR, Patten SB, Williams JV, et al. Comorbidity of major depression with substance use disorders. Can J Psychiatry 2005 Sep; 50 (10): 660-6
22. Bergh J, Holmquist M. Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 2001; 30: 103-8
23. Graves N, Birrell F, Whitby M. Effect of pressure ulcers on length of hospital stay. Infect Control Hosp Epidemiol 2005 Mar; 26 (3): 293-7
24. Walland M. Glaucoma treatment in Australia: changing patterns of therapy. Clin Experiment Ophthalmol 2004; 32: 590-6
25. Monnet DL, Molstad S, Cars O. Defined daily doses of antimicrobials reflect antimicrobial prescriptions in ambulatory care. J Antimicrob Chemother 2004 Apr 29; 53: 1109-11
26. Rahme E, Joseph L, Kong SX, et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001; 52: 185-92
27. Ricordeau P, Weill A, Vallier N, et al. The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000? Diabetes Metab 2003 Nov; 29 (5): 497-504
28. Gandjour A, Kleinschmit F, Lauterbach KW, et al. European comparison of costs and quality in the prevention of secondary complications in type 2 diabetes mellitus (2000-2001). Diabet Med 2002; 19: 594-601
29. Berto P, Tinuper P, Viaggi S, et al. Cost-of-illness in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000; 17 (2): 197-208
30. Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 2004 Dec; 27: 1034-9
31. Leong RW, Smith DW, Garas G, et al. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis. Intern Med J 2004; 34: 410-5
32. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-8
33. Dedes KJ, Szucs TD, Bodis S, et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 2004; 22 (7): 435-44
34. Mashiba S, Takahashi T, Hayashi N, et al. Features of patients with influenza virus infection examined in the emergency department of a university hospital in north-western Japan. J Int Med Res 2004; 32: 331-6
35. Wong MK, Arjandas M, Ching LK, et al. Osteoporotic hip fractures in Singapore: costs and patient's outcome. Ann Acad Med Singapore 2002; 31 (1): 3-7
36. Lindgren P, Jonsson B, Redaelli A, et al. Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer. Pharmacoeconomics 2002; 20 (2): 101-8
37. Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004 Jun 8; 91: 77-83
38. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arteriosclero Thromb Vascu Biol 2005; 25 (7): 1475-81
39. Ash AS, Ellis RP, Pope GC, et al. Using diagnoses to describe populations and predict costs. Health Care Fin Rev 2000; 21: 7-28
40. Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995; 33: 783-95
41. Deyo AR, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9
42. Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Car 2001; 39 (11): 1188-02
43. Lezzoni L, Ash AS, Daley J, et al. Risk adjustment for measuring healthcare outcomes. 2nd ed. Chicago (IL): Health Administration Press, 1997
44. Kronick R, Gilmer T, Dreyfus T, et al. Improving health-based payment for Medicaid beneficiaries. CDPS Health Care Fin Rev 2000; 21: 29-64
45. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91: 444-54
46. Crown W, Obenchain R, Englehart L, et al. Application of sample selection models to outcomes research: the case of evaluating effects of antidepressant therapy on resource utilization. Stat Med 1998; 17: 1943-58
47. D'Agostino R. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17 (19): 2265-81